By understanding complex biology through artificial intelligence, they integrate the best of human and AI capabilities to develop improved drugs and diagnostics at scale.

Through their understanding of complex biology using AI, they identify new treatments, de-risk and accelerate clinical trials, and develop diagnostic tools to reduce time to impact for patients.

Owkin was founded with this vision in mind, combining human expertise with cutting-edge technology to revolutionize the medical field.

Owkin works with top academic centers to curate, enrich, and generate deep, multimodal data that is AI-ready.

They apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials, and develop and deploy diagnostics in clinical practice.

Their drug discovery engines leverage their expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through their AI engines, they deliver novel drug targets and optimize drug positioning.

They combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

Their AI diagnostics help pre-screen for biomarkers and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

–  Therapeutic areas: Oncology, Immunology and Inflammation, Cardiovascular

–  Based in: Based in Paris (FRANCE)
Offices in New York City (USA) and in London (UK)

–  Employees: 201 – 500

– Created in: 2016